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ABSTRACT
Background: Dehydroandrographolide (DA) is the main contributor to the 
therapeutic properties of the medicinal plant Andrographis paniculata (AP). However, 
it is unknown whether DA has a hepatoprotective effect on obstructive cholestasis 
in mice and humans.
Methods: We administered DA to mice for 5 days prior to bile duct ligation (BDL) 
and for the 7 days. Liver function markers, liver histology and necrosis, compensatory 
responses of hepatocytes, liver fibrosis and the expression of hepatic fibrogenesis 
markers were evaluated in BDL mice and/or human LX-2 cells.
Results: Mice treated with DA demonstrated lower levels of serum alanine 
transarninase (ALT), milder liver damage, liver necrosis and fibrosis formation than in 
vehicle control with carboxymethylcellulose (CMC) mice after BDL. DA treatment also 
enhanced the Mrp3 expression of hepatocytes but not Mrp4 following BDL. Further, 
DA treatment in BDL mice significantly reduced liver mRNA and/or protein expression 
of Tgf-β, Col1a1, α-Sma and Mmp2. This result was also supported by hydroxyproline 
analysis. The molecular mechanisms of DA treatment were also assessed in human 
hepatic stellate cell line (LX-2 cell). DA treatment significantly inhibited Tgf-β-induced 
Col1a1, Mmp2 and α-Sma expression in human LX-2 cells. These data suggested 
that DA treatment reduced liver damage through development of a hepatic adaptive 
response and inhibition of the activation of HSCs, which led to a reduction in liver 
fibrosis formation in BDL mice.
Conclusions: DA treatment protected against liver damage and fibrosis following 
BDL and might be an effective therapy for extrahepatic cholestasis due to bile duct 
obstruction.
INTRODUCTION
Obstructive cholestasis is caused by occlusion of 
the common bile duct or its tributaries and is associated 
with reduced bile flow, hepatic accumulation of bile acids, 
progressive liver injury and development of fibrosis. 
Production and accumulation of extracellular matrix 
(ECM) constituents is the primary cause of liver fibrosis 
[1]. Furthermore, activation of hepatic stellate cells 
(HSCs) can result in increased ECM synthesis through the 
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actions of hepatic fibrolytic matrix metalloproteinases and 
convert liver parenchyma into scar tissue, leading to liver 
cirrhosis [2]. However, aside from liver transplantation, 
effective medical treatments for cirrhosis are not currently 
available. Therefore, effective inhibition of HSC activation 
is a promising therapeutic target to protect the liver against 
fibrosis in cholestatic liver diseases.
To date, ursodeoxycholic acid (UDCA) is the only 
FDA-approved drug to treat cholestatic liver disorder in 
the clinic. However, its effectiveness is limited for primary 
biliary cirrhosis (PBC) patients [3]. Although PBC has 
received attention in recent years to study the molecular 
mechanism of cholestasis, new therapeutic approaches 
have been not developed. Thus, there is a pressing need 
to develop a safe and effective agent that may facilitate 
successful treatments for cholestatic patients.
For centuries, medicinal plants have traditionally 
been used to treat liver diseases, and the toxicity 
factor appears to be low, with few side effects [4–7]. 
AP, also known as Chuan-xin-lian in Chinese, is a 
Chinese medicinal herb widely used to treat infection, 
inflammation, the common cold, fever, diarrhea, 
hypertension, cardiovascular and liver disorders [8–11]. 
In the last several years, increasing attention has been 
paid to AP because of its diverse therapeutic properties. 
The reported primary active ingredients of AP are 
several diterpene lactones, flavonoids, and polyphenols 
[12, 13]. Andrographolide and dehydroandrographolide 
are diterpenoid compounds that are believed to be 
the main contributors to the therapeutic properties of 
AP. Andrographolide has shown protective effects 
against liver damage caused by carbon tetrachloride 
[14], acetaminophen [15] and hexachlorocyclohexane 
[16]. DA (14-deoxy-11, 12-didehydroandrographolide, 
C20H28O4) has also been shown to play a role in the 
plant’s pharmacological effects, specifically exhibiting 
anti-inflammatory, anti-cancer, anti-platelet and anti-
hypertension activities in various cells and animals [11, 
17–19]. Recently, a study reported that DA possessed 
free radical scavenging and ferric reducing capacities [9, 
20]. However, the hepatoprotective effects of DA remain 
unclear. Given that AP and andrographolide have hepatic 
protective effect in human and animal model, DA may be 
an attractive candidate drug for the treatment of cholestatic 
liver diseases.
In this study, we tested the hepatic protective 
effects of DA in vivo in a mouse model of obstructive 
cholestasis and in vitro in human LX-2 cells. Our findings 
demonstrate that DA treatment significantly reduced liver 
damage and fibrosis formation following BDL in mice. In 
further elucidating the underlying molecular mechanisms, 
we found that the effectiveness of DA treatment is due 
to its ability to enhance the hepatic adaptive response, 
inhibit HSC activation and decrease ECM deposition, 
which will likely lead to reduced liver fibrosis formation 
in cholestatic disorders.
RESULTS
DA treatment reduced BDL-induced liver injury 
in mice
Figure 1A depicts the body weights and the ratios 
of liver/body weight (Figure 1B) of mice receiving either 
CMC or DA (the chemical structure is shown in Figure 
1C) at a high dose of 100 mg/kg body weight. This dose 
was considered one tenth of the proposed oral LD50 mg/
kg body weight obtained from the acute toxicity study. 
No changes in sizes, gross anatomical features or weights 
were observed (p>0.05). H&E staining demonstrated 
that the livers of both groups of mice exhibited similar 
histological features, as well as comparable liver lobule 
structures and hepatocyte densities (Figure 1D). This 
suggested that DA treatment had little toxicity in normal 
mice. We observed the levels of markers associated with 
hepatobiliary disease, including ALT, TBIL, TBA, TC 
and LDL-C in serum and/or liver tissues in sham and 
BDL mice. Biochemical analysis revealed that DA dose 
at 100 mg/kg body weight did not change the serum 
TBIL, TBA, ALT, TC or LDL-C levels in sham mice, but 
there were significantly reduced serum levels of ALT, TC 
and LDL-C in BDL mice compared to CMC-BDL mice 
(Figure 2A and Supplementary Figure 1, p<0.01 and 
p<0.05). Furthermore, DA treatment at 100 mg/kg body 
weight decreased TBIL (Figure 2B, p<0.05 or p<0.01) 
and TBA levels (Figure 2C, p<0.05 or p<0.01) in serum 
and liver tissues in BDL mice. In addition, the weight 
of the gallbladder was also observed in BDL mice. As 
shown in Figure 2D, mice treated with DA at 100 mg/
kg body weight exhibited significantly lower gallbladder 
weights than mice treated with CMC, suggesting that 
bile production was decreased in DA-BDL mice. These 
findings indicate that DA treatment improved the overall 
condition of hepatobiliary system of the cholestatic mice.
DA treatment improved liver histology in BDL 
mice
DA treatment at 100 mg/kg body weight in BDL 
mice reduced hepatocellular ballooning, the foci of 
liver bile necrosis in the periportal regions and lobular 
infiltration by neutrophils, determined by H&E staining 
(Figure 3A). Furthermore, DA at 100 mg/kg significantly 
decreased the area of bile necrosis in the parenchyma in 
BDL mice compared to CMC-BDL mice. As quantified 
by morphometric analysis of bile necrotic areas, we also 
observed significantly decreased liver damage in DA-BDL 
mice compared to CMC-BDL mice (Figure 3B, p<0.01). 
To accurately clarify whether biliary necrosis were caused 
by hepatocyte apoptosis or necrosis, TUNEL staining was 
performed for BDL mice. Figure 3C shows that TUNEL-
positive cells were not increased in the bile necrotic zones in 
CMC-BDL mice compared with DA-BDL mice (p>0.05). 
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Immunoblot analysis showed that expression of Caspase 3 
and Caspase 8 were not changed by DA treatment in BDL 
mice compared to CMC-BDL mice (Figure 3D, p>0.05). 
In addition, we also examined the effect of DA on cellular 
senescence using β-galactosidase staining in BDL mice 
liver. The number of β-alactosidase positive cells was 
significantly increased in BDL mice than in sham mice. 
But no different was seen in β-alactosidase positive cells 
number between DA-BDL mice and CMC-BDL mice 
(Figure 3E, p>0.05), suggesting that hepatocyte death 
following BDL was primarily induced by cell necrosis. 
However, DA at 50 mg/kg body weight nether altered 
serum levels of ALT and TBIL nor reduced biliary necrotic 
areas and periportal inflammation in BDL mice liver. Thus 
we chose a DA dose at 100 mg/kg for our studies.
DA enhanced the adaptive response to BDL in 
mice
The extent of liver damage in obstructive cholestasis 
is regulated by adaptive changes in hepatic membrane 
transporters [24, 25]. We assessed whether DA treatment 
altered the expression of hepatic efflux transporters in 
BDL mice. Figure 4A demonstrates that the expression 
of Mrp3 and Mrp4 (mainly basolateral transporters) was 
up-regulated in CMC-BDL mice compared to sham mice, 
according to a western blot assay. However, Mrp3 was 
further up-regulated in DA-BDL mice with the highest 
elevation at a DA dose of 100 mg (p<0.05). Examination 
of the gene expression of Mrp3 and Mrp4 also confirmed 
that DA further increased the levels of Mrp3 mRNA 
compared to the levels in CMC-BDL mice (Figure 4B, 
p<0.01). Assessment of the expression of canalicular 
efflux transporter proteins revealed increased Mdr2 
and Bsep expression, whereas decreased Mrp2 protein 
expression was seen in all BDL mice. However, there was 
no statistically significant difference after DA treatment 
(Figure 4C, p>0.05). These results suggested that up-
regulation of Mrp3 exerted an effective adaptive response 
to BDL-induced liver injury as evidenced by the reduction 
of bile infarcts in DA-BDL mice.
DA treatment inhibited liver fibrosis formation 
in BDL mice
The BDL model in mice leads to liver fibrosis via 
activation of the expression of hepatic fibrogenesis genes 
[26]. To further determine if this mechanism contributed 
Figure 1: DA treatment had no effect on the liver of mice. (A) Body weights of mice receiving either CMC or DA treatment. (B) 
The ratios of liver/body weight and (C) The chemical structure of DA. (D) H&E-stained liver histology. Data represent the means ± SEM 
of 3 independent experiments. n=10, p>0.05.
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to the improvement in liver injury in DA-BDL mice, we 
next evaluated whether DA treatment could affect hepatic 
expression of profibrogenic genes. qPCR demonstrated 
that the expression of the key genes Tgf-β, α-Sma 
and Col1a1 in hepatic fibrogenesis were significantly 
decreased in DA-BDL mice compared to CMC-BDL mice 
(Figure 5A, p<0.05 or p<0.01). A western blot analysis 
also revealed a significant reduction in α-Sma protein 
expression in DA-BDL mice compared to CMC-BDL 
mice (Figure 5B, p<0.01). Furthermore, hydroxyproline 
analysis showed significantly lower levels of this fibrosis 
marker in the livers of DA-BDL mice compared to the 
levels in livers of CMC-BDL mice (Figure 5C, p<0.01). 
This result was also supported by analysis of Sirius Red 
staining of the liver, which revealed reduced collagen 
deposits in the periportal area five days after BDL in DA-
BDL mice compared with CMC-BDL mice (Figure 5D, 
p<0.01). These data suggest that DA treatment represses 
the activation of HSCs, further reducing fibrosis formation 
in BDL mice.
The anti-fibrotic effect of DA was further verified by 
the action of hepatic fibrolytic matrix metalloproteinases. 
As shown in Figure 6, the mRNA expressions of Mmp-2 
(A), Mmp-9 (B) and Mmp-13 (C) were significantly up-
regulated in BDL mice compared to sham mice. However, 
DA treatment in BDL mice did not alter the mRNA level of 
Mmp-9 and Mmp-13, whereas the mRNA level of Mmp-
2 was significantly decreased compared to that of CMC-
BDL mice (p<0.01). Consistent with the mRNA levels, 
Mmp-2 protein expression level was greatly reduced in 
DA-BDL mice than CMC-BDL mice (Figure 6D, p<0.01). 
These data indicate that the liver protective effect exerted 
by DA treatment might be meditated through reduced 
Mmp secretion, decreasing ECM deposition following 
BDL.
DA treatment reduced col1a1 and mmp2 
expression in LX-2 cells
Because DA treatment reduced markers of hepatic 
fibrosis in BDL mice, we next assessed if this treatment 
would have the same anti-fibrotic effects in human LX-2 
cells. LX-2 cells were incubated with DA at 5, 10, and 
20 μM (IC50 10 μM) and Tgf-β for 24 h [27–29]. Figure 
7A shows that 24 h of treatment with 10 and 20 μM DA 
significantly inhibited Tgf-β-induced Col1a1 mRNA 
expression (p<0.01). DA treatment with 10 and 20 μM 
also further reduced Tgf-β-stimulated Mmp2 mRNA 
expressions in LX-2 cells (Figure 7B, p<0.01). However, 
Mmp9 and Mmp13 were not changed by DA treatments 
at any dose. Western blot analysis also showed significant 
reduction in ɑ-Sma protein expression in cells after 10 and 
20 μM DA treatment (Figure 7C, p<0.01). Moreover, low 
dose DA at 5 μM altered the Tgf-β-induced expression of 
Col1a1, Mmp2 and ɑ-Sma expression (p<0.05) in LX-2 
cells, suggesting that DA exerts its anti-fibrotic effects in 
the liver through inhibition of Col1a1, ɑ-Sma, and Mmp2 
expression.
Figure 2: Effect of DA on BDL-induced liver injury. (A) Plasma ALT, (B) total bilirubin and (C) total bile acid levels were 
significantly reduced in DA-BDL mice compared to CMC-BDL mice. (D) DA-treated mice also exhibited significantly smaller gallbladder 
weights than CMC-treated BDL mice. Data represent the means ± SEM of 3 independent experiments. n=10, * p<0.05 and **p<0.01, 
between the indicated groups.
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DISCUSSION
In this study, we assessed the liver protective effects 
of DA in vivo in a BDL cholestatic mouse model and in 
vitro in human LX-2 cells. DA treatment attenuated liver 
damage in the BDL model as demonstrated by 1) improved 
mouse liver function and histology and reduced liver bile 
infarction, necrosis and fibrosis (Figure 2&3); 2) enhanced 
liver adaptive response to BDL by up-regulating Mrp3 
expression (Figure 4); and 3) reduced liver hydroxyproline 
content and fibrotic markers (Figure 5&6). Moreover, the 
reduced liver fibrogenesis upon DA treatment was further 
confirmed in human LX-2 cells (Figure 7).
BDL-induced cholestasis results in the loss of bile 
excretory function and toxic bile accumulation, leading to 
injury of the liver parenchyma [30]. However, adaptive 
response mechanisms can compensate for the extent 
of liver injury resulting from cholestasis [31, 32]. In 
cholestasis, to compensate, the main influx transporters 
of the basolateral membrane of hepatocytes, including 
sodium/bile acid and sulfated solute cotransporter1 
(Slc10a1) and organic anion transporter (Slco1a1), are 
down-regulated, whereas main efflux transporters of the 
basolateral membrane of hepatocytes, including Mrp3, 
Mrp4 and Ostα/β, are up-regulated to reduce or accelerate 
the uptake or secretion of bile acids and other organic 
anions [33]. In addition, down-regulation of the canalicular 
membrane transporters of hepatocytes, Bsep and Mrp2, is 
associated with cholestasis [24, 34]. In the present study, 
DA treatments were able to efficiently relieve BDL-
induced liver injury by modifying hepatocellular gene and 
protein expression of Mrp3 compared to CMC-BDL mice 
(Figure 4A&4B). Up-regulation of Mrp3 can decrease 
bile acid accumulation, resulting in hepatocyte damage. 
This result was supported by our experimental results 
examining serum enzyme markers and liver histology 
(Figure 2). Although ductular reaction may represent an 
evacuation route for bile during cholestasis [35], our data 
did not show that DA treatments significantly enhanced 
bile duct proliferation, as assessed by Ck19 staining 
Figure 3: DA improved liver histology in BDL mice. (A) Representative images of H&E-stained liver sections from sham and BDL 
mice treated with either CMC or DA. Liver necrosis is shown by black arrows. Yellow arrows point toward inflammatory cell. (B) Scores of 
the double-blind assessment of liver necrotic areas (left) and inflammatory cell infiltration (right) of sham and BDL mice treated with CMC 
or DA. n=10, ** p<0.01, between the indicated groups. (C) Representative images of TUNEL-stained liver sections from sham and BDL 
mice treated with either CMC or DA (left). TUNEL-positive cell counts in the bile necrotic zones of sham and BDL mice treated with CMC 
or DA (right). Data represent the means ± SEM of 3 independent experiments. n=10, p>0.05. (D) Representative blots and densitometry 
data of procaspase3 and procaspase8 expression in BDL mice livers with and without DA treatment. Data represent the means ± SEM of 3 
independent experiments. n=3, p>0.05. (E) Representative images of β-alactosidase-stained liver sections from sham and BDL mice treated 
with either CMC or DA. Senescence cell is shown by arrows. Data represent the means ± SEM of 3 independent experiments. n=10, p>0.05.
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(data not shown). Thus, it is likely that DA treatments 
exert a cytoprotective effect in the liver directly through 
enhancing liver adaptive mechanisms to BDL, e.g., up-
regulation of Mrp3 expression.
AP, a Chinese medicinal herb, has been commonly 
used for liver disorder therapy in China. Andrographolide, 
one of the main ingredients in AP, has been shown to have 
a liver-protective effect in various animal models [14–16]. 
DA is another active ingredient of AP. However, studies on 
the effects of DA in patients and animal with liver disorder 
are limited. In a recent study, DA was shown to have anti-
oxidant properties [20], which may render protective 
effects against oxidative liver damage and fibrosis. To 
extend this observation in liver disorders, we tested the 
efficacy of DA in inhibiting the progression of cholestatic 
liver fibrosis induced by BDL in mice. Data from our study 
Figure 4: DA enhanced the adaptive response to BDL in mice. (A) Representative blots and densitometry data of Mrp3 and Mrp4 
expression in BDL mouse livers with and without DA treatment. n=5, *p<0.05 BDL-CMC versus BDL-DA. (B) Relative mRNA expression 
for Mrp3 and Mrp4 in BDL mice. n=3, **p<0.01, between indicated groups. (C) Representative blots and densitometry data of Mdr2, Bsep 
and Mrp2 expressions in BDL mice livers with and without DA treatment. Data are expressed in arbitrary units. n=3. Data represent the 
means ± SEM of 3 independent experiments.
Figure 5: DA treatment inhibited liver fibrosis formation in BDL mice. (A) Relative liver mRNA expression for Tgf-β, α-Sma 
and Col1a1. Data are expressed as the fold change relative to CMC-mice. Data were normalized to β-actin. (B) Liver α-Sma protein 
expression detected by western blotting. Data were normalized to GAPDH. (C) Liver hydroxyproline levels. (D) Representative images of 
sirius red staining of liver sections from sham and BDL mice treated with either CMC or DA. Data represent means ± SEM of 4 independent 
experiments. n=3-5, * p<0.05 and **p<0.01, between indicated groups.
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Figure 7: DA treatment reduced the expression of fibrotic marker genes/protein in human LX-2 cells. (A) mRNA 
expression of Col1a1, (B) Mmp2, Mmp-9, and Mmp-13 in human LX-2 cells. (C) α-Sma protein expression detected by western blotting. 
Data are normalized to GAPDH. Data represent means ± SEM of 4 independent experiments. n=3, * p<0.05 and ** p<0.01 between 
indicated groups.
Figure 6: DA treatment decreased ECM deposition in BDL mice. (A) Relative Liver mRNA expression for Mmp-2, Mmp-9 (B) 
and Mmp-13 (C) in sham and BDL mice. Data were normalized to β-actin. (D) Liver Mmp-2, Mmp-9 and Mmp-13 protein expressions 
detected by western blotting. Data were normalized to GAPDH. Data are expressed in arbitrary units. Data represent the means ± SEM of 
3 independent experiments. n=3, * p<0.05, ** p<0.01, between the indicated groups.
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demonstrate a significant decrease in collagen deposition 
by DA treatments in the livers of BDL mice (Figure 6). 
Moreover, this result was further supported by biochemical 
and gene expression analyses, as markers such as 
hydroxyproline content, expression of Tgf-β, α-Sma and 
Col1a1 in the livers of DA-treated mice were significantly 
decreased compared to those in CMC-treated BDL mouse 
livers (Figure 5), suggesting that DA attenuated liver 
fibrosis and that this effect was companied by suppressed 
activation of HSCs. Moreover, the anti-fibrotic effect of 
DA was also evidenced by reduced expression of Mmp2 
in the BDL model (Figure 6). Although DA has never 
been tested in clinical patients, we used a human hepatic 
stellate cell line to determine whether it would show 
the same response to DA. We treated human LX-2 cells 
with DA at different concentrations. Low dose (5 μM) 
DA had beneficial effects and altered the Tgf-β-induced 
expression of Col1a1, Mmp2 and α-Sma (Figure 7), and 
these findings were consistent with the results in the 
animal studies. Tgf-β targets HSCs of the liver and helps 
to induce the transdifferentiation of HSCs into fibrogenic 
myofibroblasts, promoting the formation of liver fibrosis 
[36–39]. Thus, the suppression of liver fibrosis progression 
by DA observed in human LX-2 cells was likely mediated 
by preventing activation of Tgf-β profibrogenic pathways.
In conclusion, our results reveal that DA reduced 
liver damage and fibrosis and promoted the development 
of a hepatic adaptive response in a mouse model of 
cholestasis and in human LX-2 cells in vitro, suggesting 
that DA, a natural compound, is an attractive candidate to 
treat patients with chronic cholestatic disorders.
MATERIALS AND METHODS
Materials
DA was purchased from the National Institution 
for the Control of Pharmaceutical and Biological 
Products in China, and its purity (> 99%) was defined 
by HPLC. All chemical reagents were obtained from 
Sigma-Aldrich (St Louis, MO, USA). ALT, low density 
lipoprotein cholesterol (LDL-C) and total cholesterol 
(TC) analysis kits were purchased from Nanjing 
Jiancheng Bioengineering Institute (Nanjing, China). 
Total bilirubin (TBIL) and total bile acid (TBA) ELISA 
kits were purchased from Huamei Bioengineering Institute 
(Wuhan, China). Polyclonal antibodies against Mrp2, 
Mrp3, Mrp4 and Bsep antibody were obtained from Santa 
Cruz Biotechnologies (Santa Cruz, CA, USA). α-Sma, 
Mmp2, Mmp9, Mmp13 and GAPDH antibodies were 
obtained from Abcam (Cambridge, UK). TRIzol reagent, 
primer sequences for a TaqMan real-time PCR kit (Mmp2, 
Mmp9 and Mmp13) and secondary antibodies were 
purchased from Invitrogen (Carlsbad, CA, USA). Tgf-β 
was purchased from R&D (Minneapolis, MN, USA). 
Quantitative polymerase chain reaction (qPCR) kit was 
obtained from Roche (Indianapolis, IN, USA). ECL was 
obtained from Thermo Scientific (Rockford, IL, USA).
Animals and experimental protocols
Adult male C57BL/6J mice (8-10 weeks old) were 
used for this study. The mice were maintained in a specific 
pathogen-free grade animal facility under a 12-h light-dark 
cycle. All procedures were approved by the Committee 
on Animal Research of Jinzhou Medical University and 
followed the ARRIVE guidelines pertaining to animal 
experimentation [21]. Mice were randomized and 
pretreated with DA by gavage at a dose of 100 mg/kg 
body weight or vehicle for 5 days (drug concentration 
equilibrium) prior to bile duct ligation, and then DA 
treatment continued for 7 days. The vehicle-treated control 
mice received an equal volume of 0.5% CMC (10 ml/kg). 
Total duration for DA treatment was 12 days. BDL was 
performed via double ligation and section of the common 
bile duct in mice. Briefly, mice were fasted (not water) 
overnight prior to the operation. Mice were anesthetized 
with 2% isoflurane inhalation and were fixed on an 
animal operating table with a heating pad. After midline 
laparotomy, the common bile duct was isolated from the 
surrounding tissue and dissected between two ligature 
knots with 8-0 nylon suture. Sham mice underwent the 
same procedure, including the mobilization of the bile 
duct, but without dissection and ligation. Mice were placed 
on a heating pad while recovering from the anesthesia 
[22]. Serum and liver tissue were collected from the BDL 
and sham mice and stored at −80°C.
Liver function analysis
Plasma ALT, TC and LDL-C were measured as an 
indicator of hepatic injury using a commercial kit. TBA 
concentration and TBIL levels in the plasma and liver 
were determined using commercial ELISA kits.
Histopathology and immunostaining
Mice were anesthetized using an over-dose of 
phenobarbital sodium via intraperitoneal injection. Then, 
the livers were removed and fixed in 4% paraformaldehyde 
for 24 h at 20°C. The samples were dehydrated using 
increasing concentrations of ethanol and embedded in 
paraffin. The sections were deparaffinized and stained 
using hematoxylin and eosin (H&E) and Sirius Red. Liver 
histology was blindly assessed for necrosis and fibrosis on 
a 1- 4+ scale.
Cells culture and treatment
The human LX-2 cell line was purchased from 
the Shanghai Institute of Biological Science (Shanghai, 
China). The cells were grown in plastic culture flasks 
under standard conditions (37°C with 5% CO2 in a 
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completely humidified atmosphere) using DMEM 
supplemented with 10% heat-inactivated FBS and 1% 
penicillin/streptomycin. Cell detachment was achieved by 
rinsing with 0.05% trypsin/0.02% EDTA solution. After 
24 h of attachment, the cells were cultured in serum-
free DMEM for 24 h and then treated with DA at an IC50 
concentration and two difference concentrations or with 
Tgf-β at 2 ng/ml for 24 h to assay the hepatic fibrogenesis 
genes. DA was dissolved in dimethyl sulfoxide (DMSO) to 
form a 20 mM stock solution, which was stored at -20°C 
and diluted to the desired final concentration in DMEM at 
the time of use.
Quantitative real-time PCR and western blot 
analysis
Total RNA was extracted from liver samples 
via homogenization in TRIzol reagent. cDNA was 
synthesized from 2 μg of total RNA using random 
hexamer primers and 200 U of Moloney murine leukemia 
virus reverse transcriptase for 1 h at 37°C. qPCR was 
performed using a LightCycler with a FastStart DNA 
MasterPLUS SYBR Green I kit. β-Actin was used as a 
reference gene. The results are reported as normalized 
and calibrated ratios. The primers were as follows: 
5‘-CCACCATGTACCCAGGCATT-3’ (sense) and 
5’-CCGGACTCATCGTACTCCTG-3’ (antisense) for 
β-actin; 5’-GAAACCCGAGGTATGCTTGA-3’ (sense) 
and 5’-GACCAGGAGGACCAGGAAGT-3’ (antisense) 
for Col1a1; 5’-GTCAGACATTCGGGAAGCAG-3’ 
(sense) and 5’-GCGTATCAGTGGGGGTCA-3’ 
(antisense) for Tgf-β. Mmp2, Mmp9 and Mmp13 were 
examined using an ABI kit.
Liver total proteins and membrane proteins were 
isolated from the mouse liver tissues. Western blot 
analysis was performed as previously described with 
some modifications [23]. Briefly, samples were loaded 
onto an 8-10% SDS-polyacrylamide gel (20 μg of protein/
lane) for electrophoresis, and proteins were transferred to 
a polyvinylidene difluoride membrane. The membrane 
was subsequently incubated with a primary antibody 
overnight at 4°C. Following washing with TBS, the 
membrane was incubated with a horseradish peroxidase 
(HRP)-linked secondary antibody at room temperature for 
1 h in the dark. The bands were developed using enhanced 
chemiluminescence. The relative quantities of protein 
expression were analyzed using Image J software.
Statistical analysis
The data are shown as the mean ± standard error 
of the mean (SEM). All experiments were performed 
in triplicate. All data were estimated using Student’s 
t-test or chi square test for two-group data sets and one-
way ANOVA followed by Bonferroni’s post hoc test to 
compare more than two groups, using GraphPad Prism 
software, version 5.0. A p value < 0.05 was considered to 
be statistically significant.
Author contributions
Conceived and designed the experiments: LHL, 
ZYW. Performed the experiments: ZYW, XFL, JHH, 
JZM, JX, CJY, LHL. Analyzed the data: LHL, ZYW, XFL. 
Contributed reagents/materials/analysis tools: LHL, ZYW, 
XFL. Wrote the paper: LHL.
ACKNOWLEDGMENTS AND FUNDING
This study was supported by the National Natural 
Science Foundation of China [No. 31571184] and 
Liaoning BaiQianWan Talents Program [No. 2017101].
CONFLICTS OF INTEREST
The authors declare no competing financial interests.
REFERENCES
1. Guo J, Friedman SL. Hepatic fibrogenesis. Semin Liver Dis. 
2007;27:413-26. https://doi.org/10.1055/s-2007-991517.
2. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 
2005;115:209-18. https://doi.org/10.1172/JCI24282.
3. Lindor KD, Kowdley KV, Luketic VA, Harrison ME, 
McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz 
J, Keach J, Mooney J, Sargeant C, Braaten J, et al. High-
dose ursodeoxycholic acid for the treatment of primary 
sclerosing cholangitis. Hepatology. 2009;50:808-14. https://
doi.org/10.1002/hep.23082.
4. Negi AS, Kumar JK, Luqman S, Shanker K, Gupta MM, 
Khanuja SP. Recent advances in plant hepatoprotectives: 
a chemical and biological profile of some important leads. 
Med Res Rev 2008; 28:746-72. https://doi.org/10.1002/
med.20115.
5. Lin HJ, Chen JY, Lin CF, Kao ST, Cheng JC, Chen HL, 
Chen CM. Hepatoprotective effects of Yi Guan Jian, an 
herbal medicine, in rats with dimethylnitrosamine-induced 
liver fibrosis. J Ethnopharmacol. 2011;134:953-60. https://
doi.org/10.1016/j.jep.2011.02.013.
6. Wasser S, Ho JM, Ang HK, Tan CE. Salvia miltiorrhiza 
reduces experimentally-induced hepatic fibrosis in rats. J 
Hepatol. 1998;29:760-71.
7. Lee TY, Wang GJ, Chiu JH, Lin HC. Long-term 
administration of Salvia miltiorrhiza ameliorates 
carbon tetrachlorideinduced hepatic fibrosis in rats. 
J Pharm Pharmacol. 2003;55:1561-8. https://doi.
org/10.1211/0022357022098.
8. Roxas M, Jurenka J. Colds and influenza: a review of 
diagnosis and conventional, botanical and nutritional 
considerations. Altern Med Rev. 2007;12:25-48.
Oncotarget87912www.impactjournals.com/oncotarget
9. Kamdem RE, Sang S, Ho CT. Mechanism of the superoxide 
scavenging activity of neoandrographolide - a natural 
product from Andrographis paniculata Nees. J Agric Food 
Chem. 2002; 50: 4662-5.
10. Yoopan N, Thisoda P, Rangkadilok N, Sahasitiwat S, 
Pholphana N, Ruchirawat S, Satayavivad J. Cardiovascular 
effects of 14-deoxy-11,12-didehydroandrographolide and 
Andrographis paniculata extracts. Planta Med. 2007;73:503-
11. https://doi.org/10.1055/s-2007-967181.
11. Chao WW, Kuo YH, Lin BF. Anti-inflammatory Activity 
of New Compounds from Andrographis paniculata by 
NF-KB Transactivation Inhibition. J Agric Food Chem. 
2010;58:2505-12. https://doi.org/10.1021/jf903629j.
12. Koteswara Rao Y, Vimalamma G, Rao CV, Tzeng YM. 
Flavonoids and andrographolides from Andrographis 
paniculata. Phytochemistry. 2004;65:2317-21. https://doi.
org/10.1016/j.phytochem.2004.05.008.
13. Li W, Xu X, Zhang H, Ma C, Fong H, van Breemen R, 
Fitzloff J. Secondary metabolites from Andrographis 
paniculata. Chem Pharm Bull (Tokyo). 2007;55:455-8.
14. Ye JF, Zhu H, Zhou ZF, Xiong RB, Wang XW, Su LX, 
Luo BD. Protective mechanism of andrographolide against 
carbontetrachloride-induced acute liver injury in mice. Biol 
Pharm Bull. 2011;34:1666-70.
15. Roy P, Das S, Auddy RG, Saha A, Mukherjee A. Engineered 
and rographolide nano particles mitigate paracetamol 
hepatotoxicity in mice. Pharm Res. 2013;30:1252-62. 
https://doi.org/10.1007/s11095-012-0964-5.
16. Trivedi NP, Rawal UM, Patel BP. Hepatoprotective effect 
ofandrographolide against hexachlorocyclohexane-induced 
oxidative injury. Integr Cancer Ther. 2007;6:271-80. https://
doi.org/10.1177/1534735407305985.
17. Awang K, Abdullah NH, Hadi AH, Fong YS. Cardiovascular 
activity of labdane diterpenes from Andrographis 
paniculata in isolated rat hearts. J Biomed Biotechnol. 
2012;2012:876458. https://doi.org/10.1155/2012/876458.
18. Thisoda P, Rangkadilok N, Pholphana N, 
Worasuttayangkurn L, Ruchirawat S, Satayavivad J. 
Inhibitory effect of Andrographis paniculata extract 
and its active diterpenoids on platelet aggregation. Eur J 
Pharmacol. 2006;553:39-45. https://doi.org/10.1016/j.
ejphar.2006.09.052.
19. Hsieh MJ, Lin CW, Chiou HL, Yang SF, Chen MK. 
Dehydroandrographolide, an iNOS inhibitor, extracted 
from from Andrographis paniculata (Burm.f.) Nees, 
induces autophagy in human oral cancer cells. Oncotarget. 
2015;6:30831-49. https://doi.org/10.18632/oncotarget.5036.
20. Zhao Y, Kao CP, Wu KC, Liao CR, Ho YL, Chang YS. 
Chemical Compositions, Chromatographic Fingerprints and 
Antioxidant Activities of Andrographis Herba. Molecules. 
2014;19:18332-50.
21. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman 
DG. Improving bioscience research reporting: the 
ARRIVE guidelines for reporting animal research. PLoS 
Biol. 2010;8:e1000412. https://doi.org/10.1371/journal.
pbio.1000412.
22. Mennone A, Soroka CJ, Cai SY, Harry K, Adachi M, 
Hagey L, Schuetz JD, Boyer JL. Mrp4−/− mice have an 
impaired cytoprotective response in obstructive cholestasis. 
Hepatology. 2006;43:1013-21. https://doi.org/10.1002/
hep.21158.
23. Li L, Weng Z, Yao C, Song Y, Ma T. Aquaporin-1 
Deficiency Protects Against Myocardial Infarction by 
Reducing Both Edema and Apoptosis in Mice. Sci Rep. 
2015;5:13807. https://doi.org/10.1038/srep13807.
24. Trauner M, Boyer JL. Bile salt transporters: molecular 
characterization, function, and regulation. Physiol 
Rev. 2003;83:633-71. https://doi.org/10.1152/
physrev.00027.2002.
25. Zollner G, Fickert P, Silbert D, Fuchsbichler A, Marschall 
HU, Zatloukal K, Denk H, Trauner M. Adaptive changes 
in hepatobiliary transporter expression in primary biliary 
cirrhosis. J Hepatol. 2003;38:717-27.
26. Friedman SL. Mechanisms of hepatic fibrogenesis. 
Gastroenterology. 2008;134:1655-69. https://doi.
org/10.1053/j.gastro.2008.03.003.
27. Liu Y, Liu H, Meyer C, Li J, Nadalin S, Königsrainer 
A,Weng H, Dooley S, ten Dijke P. Transforming growth 
factor-β (TGF-β)-mediated connective tissue growth factor 
(CTGF) expression in hepatic stellate cells requires Stat3 
signaling activation. J Biol Chem. 2013;288:30708-19. 
https://doi.org/10.1074/jbc.M113.478685.
28. Zheng S, Chen A. Curcumin suppresses the expression 
of extracellular matrix genes in activated hepatic stellate 
cells by inhibiting gene expression of connective 
tissue growth factor. Am J Physiol Gastrointest Liver 
Physiol. 2006;290:G883-93. https://doi.org/10.1152/
ajpgi.00450.2005.
29. Yu DK, Zhang CX, Zhao SS, Zhang SH, Zhang H, 
Cai SY, Shao RG, He HW. The anti-fibrotic effects of 
epigallocatechin-3-gallate in bile duct-ligated cholestatic 
rats and human hepatic stellate LX-2 cells are mediated 
by the PI3K/Akt/Smad pathway. Acta Pharmacol Sin. 
2015;36:473-82. https://doi.org/10.1038/aps.2014.155.
30. Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of 
cholestasis. N Engl J Med. 1998;339:1217-27. https://doi.
org/10.1056/NEJM199810223391707.
31. Yang F, Xu Y, Xiong A, He Y, Yang L, Wan YJ, Wang Z. 
Evaluation of the protective effect of RheiRadixetRhizoma 
against alpha-naphthylisothiocya-nate induced liver injury 
based on metabolic profile of bile acids. J Ethnopharmacol. 
2012;144:599-604. https://doi.org/10.1016/j.
jep.2012.09.049.
32. Wagner M, Fickert P, Zollner G, Fuchsbichler A, Silbert 
D, Tsybrovskyy O, Zatloukal K, Guo GL, Schuetz JD, 
Gonzalez FJ, Marschall HU, Denk H, Trauner M. Role 
of farnesoid X receptor in determining hepatic ABC 
Oncotarget87913www.impactjournals.com/oncotarget
transporter expression and liver injury in bile duct-ligated 
mice. Gastroenterology. 2003;125:825-38.
33. Paumgartner G. Medical treatment of cholestatic liver 
diseases: from pathobiology to pharmacological targets. 
World J Gastroenterol. 2006;12:4445-51.
34. Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Weiglein 
AH, Lammert F, Marschall HU, Tsybrovskyy O, Zatloukal 
K, Denk H, Trauner M. Ursodeoxycholic acid aggravates 
bile infarcts in bile duct-ligated and Mdr2 knockout 
mice via disruption of cholangioles. Gastroenterology. 
2002;123:1238-51.
35. Beaussier M, Wendum D, Fouassier L, Rey C, Barbu 
V, Lasnier E, Lienhart A, Scoazec JY, Rosmorduc O, 
Housset C. Adaptative bile duct proliferative response in 
experimental bile duct ischemia. J Hepatol. 2005;42:257-
65. https://doi.org/10.1016/j.jhep.2004.10.025.
36. Parola M, Marra F, Pinzani M. Myofibroblast - like cells 
and liver fibrogenesis: Emerging concepts in a rapidly 
moving scenario. Mol Aspects Med. 2008;29:58-66. https://
doi.org/10.1016/j.mam.2007.09.002.
37. Beljaars L, Daliri S, Dijkhuizen C, Poelstra K, Gosens R. 
WNT-5A regulates TGF-β-related activities in liver fibrosis. 
Am J Physiol Gastrointest Liver Physiol. 2017;312:G219-
27. https://doi.org/10.1152/ajpgi.00160.2016.
38. Spanjer AI, Baarsma HA, Oostenbrink LM, Jansen SR, 
Kuipers CC, Lindner M, Postma DS, Meurs H, Heijink 
IH, Gosens R, Königshoff M. TGF-β-induced profibrotic 
signaling is regulated in part by the WNT receptor 
Frizzled-8. FASEB J. 2016;30:1823-35. https://doi.
org/10.1096/fj.201500129.
39. Gil MN, Choi DR, Yu KS, Jeong JH, Bak DH, Kim DK, 
Lee NS, Lee JH, Jeong YG, Na CS, Na DS, Ryu KH, Han 
SY. Rhus verniciflua Stokes attenuates cholestatic liver 
cirrhosis-induced interstitial fibrosis via Smad3 down-
regulation and Smad7 up-regulation. Anat Cell Biol. 
2016;49:189-98. https://doi.org/10.5115/acb.2016.49.3.189.
